Spurred By Necessity, Industry And Academia Are Learning To Share
After a prior era of failed collaborations, industry and academia are increasingly joining forces in ways that better accommodate each others’ capabilities and goals – and, they hope, will create more value and ultimately greater improvements to human health.
You may also be interested in...
Promising academic results prove elusive when the experiments are run again, threatening reputations and wasting industry resources. Everyone is scrambling for a fix, but is the problem as bad as it seems, and do we really need a top-down solution?
Pfizer’s partnership with the Alliance for Lupus Research to co-fund translational projects within the context of the pharma’s CTI program is a first. It’s a novel way to speed promising science into the clinic. But can Pfizer, a non-profit research foundation, and academic researchers reconcile their new roles and variant cultures to make the model work?
SHANGHAI - China could serve as the catalyst for a new model of dealmaking that emphasizes more flexible and strategic partnerships to drive R&D productivity, but only if Big Pharma is willing to take "calculated risks," according to Bayer Healthcare AG Chairman Jorg Reinhardt